We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Drug Candidates Help Cells to Understand Nonsense Mutations

By LabMedica International staff writers
Posted on 13 Oct 2009
Two chemical compounds have been identified that are able to prevent the premature termination of DNA translation into protein that is caused by the presence of "nonsense mutations.”

These nonsense mutations cause the loss of vital proteins that can lead to deadly genetic disorders such as muscular dystrophy and ataxia telangiectasia (AT), a progressive neurological disease that strikes young children.

In the current study investigators at the University of California, Los Angeles (UCLA; USA) used AT as a model system to screen more than 34,000 chemical compounds for the ability to induce the cell's protein synthetic machinery to "read around" the nonsense mutation that prevents manufacture of the ATM protein, which is missing from the cells of children with the disease.

They reported in the September 28, 2009, edition of The Journal of Experimental Medicine that two compounds consistently induced functional ATM protein in ATM-deficient cells containing disease-causing nonsense mutations, as demonstrated by direct measurement of ATM protein, restored ATM kinase activity, and colony survival assays for cellular radiosensitivity. More...
The two compounds also demonstrated a similar activity in mdx mouse-myotube cells carrying a nonsense mutation and induced significant amounts of dystrophin protein, the protein lacking in muscular dystrophy.

"When DNA changes, such as nonsense mutations, occur in the middle rather than the end of a protein producing signal, they act like a stop sign that tells the cell to prematurely interrupt protein synthesis," explained senior author Dr. Richard Gatti, professor of pathology, laboratory medicine, and human genetics at UCLA. "These nonsense mutations cause the loss of vital proteins that can lead to deadly genetic disorders."

Related Links:

University of California, Los Angeles



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
HPV Test
Allplex HPV28 Detection
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.